138
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Structural, vibrational, quantum chemical and thermal investigation of a nutraceutical drug in new zwitterionic cocrystal form (nicotinic acid: catechol) with enhanced cytotoxic activity in cervical cancer HeLa cell line

, , &
Pages 5903-5916 | Received 18 Nov 2020, Accepted 06 Jan 2021, Published online: 21 Jan 2021
 

Abstract

Nicotinic acid is an aphrodisiac, co-crystalized with catechol [NICCAT] in Zwitterionic structure used as unorthodox drugs. The present study, investigates its molecular structure, using X-ray diffraction and q chemical optimization technique. An examination of single-crystal XRD reported that crystal packing was highly stabilized with N.H···O and O-H···O. Hydrogen bond synthons. Besides, a weak C-H···O affinity was also contributed to the powerful molecular construction in crystal packing. To geometrically optimize the molecular structure, we employed the Density Functional Theory (DFT), by adopting the B3LYP function and Hartree-Fock (HF) level, with 6-311++G (d, p) a basic set. Moreover, spectral analyses were detected within an excitation range of 4000–400 cm−1 using FT.IR and FT-Raman spectroscopy. A comprehensive analysis was executed by comparing optimized molecular geometries and computed excitation spectra with their respective experimental model counterparts. NICCAT thermodynamic functions were detected in the range of 100–1000 K. The thermal strong stability of developed crystals was evaluated by TGA/DTA measured. Powerful biological actions on humans cervical cancer cell line was observed and proved to be effective. The in vitro and in silico anticancer studies show that NICCAT has better activity against human cervical cancer cell line (HeLa) and in bioinformatics analysis.

Graphical Abstract

Communicated by Ramaswamy H. Sarma

Acknowledgements

One of the authors SA thanks to the Department of Science and Technology, SERB for the financial support of this work in the form of the Fast Track Research Project scheme.

Disclosure statement

The authors declared that there are no conflicts of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.